DP
URGN icon

DSAM Partners’s UroGen Pharma URGN Stock Holding History

DSAM Partners’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-127,588
Closed -$6.35M – 133
2018
Q2 		$6.35M Sell
127,588
-66,662
-34% -$3.88M 1.28% 22
2018
Q1 		$9.65M Buy
194,250
+57,750
+42% +$2.89M 1.64% 24
2017
Q4 		$5.08M Buy
136,500
+62,000
+83% +$2.21M 0.85% 22
2017
Q3 		$2.35M Buy
+74,500
New +$1.64M 0.33% 45

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

DSAM Partners's URGN Position: Q3 2018 in Review

DSAM Partners sold out of UroGen Pharma (URGN) in Q3 2018, closing a stake of 127,588 shares — an estimated $6.35M sold.

DSAM Partners first reported a position in URGN in Q3 2017 and held it in 4 quarters. The position peaked at $9.65M in Q1 2018. 71 funds tracked by Wall St. Rank hold URGN as of Q3 2018.

  • DSAM Partners reported no remaining UroGen Pharma position as of Q3 2018 after selling out during the quarter.
  • DSAM Partners sold 127,588 UroGen Pharma shares in Q3 2018, an estimated $6.35M.
  • DSAM Partners first reported a position in UroGen Pharma in Q3 2017 and held it in 4 quarters.
  • DSAM Partners's UroGen Pharma position peaked at $9.65M in Q1 2018.
  • 71 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2018.

Based on DSAM Partners's 13F filing for Q3 2018, filed 14 Nov 2018.